Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2020

Open Access 01-12-2020 | Research article

Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients

Authors: Piero Ruscitti, Onorina Berardicurti, Daniela Iacono, Ilenia Pantano, Vasiliki Liakouli, Francesco Caso, Giacomo Emmi, Rosa Daniela Grembiale, Francesco Paolo Cantatore, Fabiola Atzeni, Federico Perosa, Raffaele Scarpa, Giuliana Guggino, Francesco Ciccia, Antonio Barile, Paola Cipriani, Roberto Giacomelli

Published in: Arthritis Research & Therapy | Issue 1/2020

Login to get access

Abstract

Background

Adult-onset Still’s disease (AOSD) is a systemic inflammatory disorder of unknown aetiology usually affecting young adults. Interestingly, recent evidence from the juvenile counterpart of AOSD suggested the emergent high fatality rate of lung disease (LD) in these patients. In this work, we aimed to characterise LD in AOSD, to identify associated clinical features and predictive factors, and to describe long-term outcomes of the disease comparing patients with LD and those without.

Methods

A retrospective assessment of prospectively followed patients, from January 2001 to December 2019, was provided to describe the rate of LD in AOSD, associated clinical features and predictive factors, and long-term outcomes. Patients with AOSD, who were included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort, were assessed.

Results

Out of 147 patients included in GIRRCS cohort, 18 (12.25%) patients were reported to be affected by LD, at the time of diagnosis of AOSD, who were characterised by older age, a higher prevalence of myalgia, of lymph node involvement, of pleuritis, and abdominal pain. Furthermore, patients with LD showed higher values of systemic score and ferritin. Among those clinical variables, older age and systemic score were also independently predictors of LD. Chest CT scans were also obtained, and the most common finding was the peripheral consolidations in 8 (44.4%) patients. Finally, a higher mortality rate, of 38.9%, was registered in patients with LD than others, since it was associated with a significant decreased survival rate.

Conclusions

The presence of LD could suggest an emergent cause of mortality in AOSD, as observed in juvenile counterpart recognising a further marker of severity and poor prognosis to be careful evaluated. Patients with LD were also characterised by some clinical features, higher values of systemic score and ferritin than the others, identifying a subset of patients mostly burdened by systemic signs and symptoms. Although specific designed future studies are needed to fully elucidate the significance of LD in AOSD, a more accurate evaluation and management of this feature could improve the long-term outcomes of these patients.
Literature
1.
go back to reference Ruscitti P, Giacomelli R. Pathogenesis of adult onset still’s disease: current understanding and new insights. Expert Rev Clin Immunol. 2018;14:65–976. Ruscitti P, Giacomelli R. Pathogenesis of adult onset still’s disease: current understanding and new insights. Expert Rev Clin Immunol. 2018;14:65–976.
2.
go back to reference Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–22.PubMed Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–22.PubMed
3.
go back to reference Fautrel B. Adult onset Still’s disease. Best Pract Res Clin Rheumatol. 2008;22:773–92.PubMed Fautrel B. Adult onset Still’s disease. Best Pract Res Clin Rheumatol. 2008;22:773–92.PubMed
4.
go back to reference Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14:603–18.PubMedPubMedCentral Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14:603–18.PubMedPubMedCentral
5.
go back to reference Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.PubMedPubMedCentral Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.PubMedPubMedCentral
6.
go back to reference Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.PubMed Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.PubMed
7.
go back to reference Li S, Zheng S, Tang S, Pan Y, Zhang S, Fang H, Qiao J. Autoinflammatory pathogenesis and targeted therapy for adult-onset Still’s disease. Clin Rev Allergy Immunol. 2020;58:71–81.PubMed Li S, Zheng S, Tang S, Pan Y, Zhang S, Fang H, Qiao J. Autoinflammatory pathogenesis and targeted therapy for adult-onset Still’s disease. Clin Rev Allergy Immunol. 2020;58:71–81.PubMed
8.
go back to reference Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519–30.PubMed Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10:1519–30.PubMed
9.
go back to reference Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13:1089–97.PubMed Ruscitti P, Ursini F, Cipriani P, De Sarro G, Giacomelli R. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13:1089–97.PubMed
10.
go back to reference Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.PubMedPubMedCentral Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.PubMedPubMedCentral
11.
go back to reference Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.PubMed Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, et al. Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev. 2017;16:16–21.PubMed
12.
go back to reference Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;0:1–10. Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;0:1–10.
13.
go back to reference Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71:1943–54.PubMedPubMedCentral Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71:1943–54.PubMedPubMedCentral
14.
go back to reference Sato H, Yokoe I, Nishio S, Onishi T, Takao T, Kobayashi Y, et al. A case of adult onset Still’s disease complicated with cryptogenic organizing pneumonia. Intern Med. 2011;50:247–51.PubMed Sato H, Yokoe I, Nishio S, Onishi T, Takao T, Kobayashi Y, et al. A case of adult onset Still’s disease complicated with cryptogenic organizing pneumonia. Intern Med. 2011;50:247–51.PubMed
15.
go back to reference Ak O, Ozer S, Cağ Y, Karagöz G. An adult onset Still’s disease mimicking pneumonia. Rheumatol Int. 2012;32:2539–41.PubMed Ak O, Ozer S, Cağ Y, Karagöz G. An adult onset Still’s disease mimicking pneumonia. Rheumatol Int. 2012;32:2539–41.PubMed
16.
go back to reference Gerfaud-Valentin M, Cottin V, Jamilloux Y, Hot A, Gaillard-Coadon A, Durieu I, et al. Parenchymal lung involvement in adult-onset still disease: a STROBE-compliant case series and literature review. Medicine. 2016;95(30):e4258.PubMedPubMedCentral Gerfaud-Valentin M, Cottin V, Jamilloux Y, Hot A, Gaillard-Coadon A, Durieu I, et al. Parenchymal lung involvement in adult-onset still disease: a STROBE-compliant case series and literature review. Medicine. 2016;95(30):e4258.PubMedPubMedCentral
17.
go back to reference Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMed Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–30.PubMed
18.
go back to reference Ruscitti P, Iacono D, Ciccia F, Emmi G, Cipriani P, Grembiale R, et al. Macrophage activation syndrome in patients affected by adult onset Still’s disease: analysis of survival rate and predictive factors in GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. J Rheumatol. 2018;45:864–72.PubMed Ruscitti P, Iacono D, Ciccia F, Emmi G, Cipriani P, Grembiale R, et al. Macrophage activation syndrome in patients affected by adult onset Still’s disease: analysis of survival rate and predictive factors in GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort. J Rheumatol. 2018;45:864–72.PubMed
19.
go back to reference Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–14.PubMedPubMedCentral Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–14.PubMedPubMedCentral
20.
go back to reference Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–20.PubMed Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–20.PubMed
21.
go back to reference Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyükasık Y, Karadag O, et al. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scand J Rheumatol. 2017;46:44–8.PubMed Batu ED, Erden A, Seyhoğlu E, Kilic L, Büyükasık Y, Karadag O, et al. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scand J Rheumatol. 2017;46:44–8.PubMed
22.
go back to reference Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O, et al. Managing adult-onset Still’s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (Baltimore). 2019;98:e15123. Ruscitti P, Cipriani P, Liakouli V, Guggino G, Carubbi F, Berardicurti O, et al. Managing adult-onset Still’s disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (Baltimore). 2019;98:e15123.
23.
go back to reference Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Caso F, et al. Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort. Rheumatol Int. 2020;40:107–13.PubMed Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Caso F, et al. Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort. Rheumatol Int. 2020;40:107–13.PubMed
24.
go back to reference Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online. 2015;13:50. Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online. 2015;13:50.
25.
go back to reference Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol. 2017;36:2839–45.PubMed Ruscitti P, Rago C, Breda L, Cipriani P, Liakouli V, Berardicurti O, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol. 2017;36:2839–45.PubMed
26.
go back to reference Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.PubMed Pay S, Türkçapar N, Kalyoncu M, Simşek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–44.PubMed
27.
go back to reference Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A. Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.PubMed Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A. Cytokine profile in adult-onset Still’s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.PubMed
28.
go back to reference Athreya BH, Doughty RA, Bookspan M, Schumacher HR, Sewell EM, Chatten J. Pulmonary manifestations of juvenile rheumatoid arthritis:a report of eight cases and review. Clin Chest Med. 1980;1:361–74.PubMed Athreya BH, Doughty RA, Bookspan M, Schumacher HR, Sewell EM, Chatten J. Pulmonary manifestations of juvenile rheumatoid arthritis:a report of eight cases and review. Clin Chest Med. 1980;1:361–74.PubMed
29.
go back to reference Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65:745–52. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65:745–52.
30.
go back to reference Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–9.
31.
go back to reference Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.PubMed Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.PubMed
32.
go back to reference Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291–8.PubMed Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still’s disease. Rheumatol Int. 2012;32:1291–8.PubMed
33.
go back to reference Zeng T, Zou YQ, Wu MF, Yang CD. Clinical features and prognosis of adult-onset Still’s disease: 61 cases from China. J Rheumatol. 2009;36:1026–31.PubMed Zeng T, Zou YQ, Wu MF, Yang CD. Clinical features and prognosis of adult-onset Still’s disease: 61 cases from China. J Rheumatol. 2009;36:1026–31.PubMed
34.
go back to reference Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Carubbi F, Berardicurti O, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? Expert Rev Clin Immunol. 2017;13:1041–7.PubMed Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Carubbi F, Berardicurti O, et al. Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? Expert Rev Clin Immunol. 2017;13:1041–7.PubMed
35.
go back to reference Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F, et al. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clin Exp Immunol. 2018;191:220–8.PubMed Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F, et al. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clin Exp Immunol. 2018;191:220–8.PubMed
36.
go back to reference Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:166–72.PubMed Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:166–72.PubMed
37.
go back to reference Liu Y, Lightfoot YL, Seto N, Carmona-Rivera C, Moore E, Goel R, et al. Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7–dependent lupus. JCI Insight. 2018;3:124729.PubMed Liu Y, Lightfoot YL, Seto N, Carmona-Rivera C, Moore E, Goel R, et al. Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7–dependent lupus. JCI Insight. 2018;3:124729.PubMed
38.
go back to reference GTEx Consortium. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648–60.PubMedCentral GTEx Consortium. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648–60.PubMedCentral
39.
go back to reference Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12:259–68.PubMedPubMedCentral Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12:259–68.PubMedPubMedCentral
40.
go back to reference Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16:911–24.PubMed Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017;16:911–24.PubMed
41.
go back to reference Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Onorina Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmun Rev. 2019;18:93–106.PubMed Giacomelli R, Afeltra A, Alunno A, Bartoloni-Bocci E, Onorina Berardicurti O, Bombardieri M, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmun Rev. 2019;18:93–106.PubMed
Metadata
Title
Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients
Authors
Piero Ruscitti
Onorina Berardicurti
Daniela Iacono
Ilenia Pantano
Vasiliki Liakouli
Francesco Caso
Giacomo Emmi
Rosa Daniela Grembiale
Francesco Paolo Cantatore
Fabiola Atzeni
Federico Perosa
Raffaele Scarpa
Giuliana Guggino
Francesco Ciccia
Antonio Barile
Paola Cipriani
Roberto Giacomelli
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2020
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-020-02245-5

Other articles of this Issue 1/2020

Arthritis Research & Therapy 1/2020 Go to the issue